Hemostasis in malignancy.
Hemostatic abnormalities are present in a majority of patients with metastatic cancer. These abnormalities can be categorized as 1) increased platelet aggregation and activation, 2) abnormal activation of coagulation cascade, 3) release of plasminogen activator, and 4) decreased hepatic synthesis of anticoagulant proteins like Protein C and antithrombin III. The abnormal activation of coagulation cascade is mediated through release of Tissue Factor, Factor X activators, and other miscellaneous procoagulants from the plasma membrane vesicles of tumor cells. Macrophages of a tumor-bearing host also produce increased amounts of Tissue Factor. Production of Factor X activators and macrophage Tissue Factor is decreased by warfarin. The ability of the tumor cells to produce platelet-aggregating activity and plasminogen activator parallels their metastatic potential in animal and experimental systems. These studies also show that antiplatelet agents and antibodies against plasminogen activator can suppress the metastatic process. One or more laboratory abnormalities of hemostasis can be shown in up to 95% of patients with metastatic cancer. These abnormalities, however, are unable to predict subsequent development of thromboembolic or hemorrhagic complications. Clinical complications occur in 9-15% of the patients in the form of thrombotic or hemorrhagic disorders. The therapy of tumor-related coagulopathy should be guided by its clinical expression. Subclinical DIC should not be treated. Coumadin is generally ineffective for therapy of thrombosis in cancer patients. There is no consensus regarding the use of heparin in acute promyelocytic leukemia (APL). The defibrination in APL may be from disseminated intravascular coagulation as well as systemic fibrinolysis, as shown by decreased alpha 2 antiplasmin levels. In such cases, epsilon aminocaproic acid plus heparin therapy may be of benefit.
Department of Medicine, Loyola University Stritch School of Medicine, Maywood, IL 60153.
S
S
Nand
H
H
Messmore
D000990:Antithrombin III / Q000096:biosynthesis; D001777:Blood Coagulation / Q000502:physiology; D001778:Blood Coagulation Disorders / Q000150:complications / Q000209:etiology / Q000628:therapy; D006470:Hemorrhage / Q000209:etiology; D006487:Hemostasis; D006801:Humans; D008099:Liver / Q000378:metabolism; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000378:metabolism; D010960:Plasminogen Activators / Q000502:physiology; D015539:Platelet Activation; D010974:Platelet Aggregation; D011486:Protein C / Q000096:biosynthesis; D013923:Thromboembolism / Q000150:complications
D011486:Protein C; D000990:Antithrombin III; D010960:Plasminogen Activators